High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses

Cytometry Part A

Volumn 79 A, Issue 8, 2011, Pages 603-612

  Pollara, Justin ^a   Hart, Lydia ^a   Brewer, Faraha ^a   Pickeral, Joy ^a   Packard, Beverly Z ^b   Hoxie, James A ^c   Komoriya, Akira ^b   Ochsenbauer, Christina ^d   Kappes, John C ^d   Roederer, Mario ^e   Huang, Ying ^f   Weinhold, Kent J ^a   Tomaras, Georgia D ^a   Haynes, Barton F ^a   Montefiori, David C ^a   Ferrari, Guido ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b OncoImmunin Inc   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d University of Alabama at Birmingham   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f USA   (United States)

Author keywords

ADCC; Fc gamma receptors; Granzyme B; High throughput; HIV; NK; SIV

Indexed keywords

FC RECEPTOR; GRANZYME; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CYTOLOGY; FLOW CYTOMETRY; HAPLORHINI; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; NATURAL KILLER CELL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; FLOW CYTOMETRY; GRANZYMES; HAPLORHINI; HIGH-THROUGHPUT SCREENING ASSAYS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, IGG; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

EID: 79960555557     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.21084     Document Type: Article

References (35)

1. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983; 148: 785-794.
2. Lyerly HK, Matthews TJ, Langlois AJ, Bolognesi DP, Weinhold KJ. Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to determinants on normal lymphocytes and expressed by infected cells serves as targets for immune attack. Proc Natl Acad Sci USA 1987; 84: 3797-3801.
3. Kohl S, Charlebois ED, Sigouroudinia M, Goldbeck C, Hartog K, Sekulovich RE, Langenberg AG, Burke RL. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J Infect Dis 2000; 181: 335-339.
4. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136: 4480-4486.
5. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97: 3146-3151.
6. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G, Sykora KW, Schmidt RE. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001; 31: 3121-3127.
7. Ljunggren K, Moschese V, Broliden PA, Giaquinto C, Quinti I, Fenyö EM, Wahren B, Rossi P, Jondal M. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990; 161: 198-202.
8. Nag P, Kim J, Sapiega V, Landay AL, Bremer JW, Mestecky J, Reichelderfer P, Kovacs A, Cohn J, Weiser B, et al. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 2004; 190: 1970-1978.
9. Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174: 2185-2189.
10. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5: e1000433.
11. Hessell AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, Bakker JM, Lanigan CMS, Landucci G, Forthal DN, Parren PWHI, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449: 101-104.
12. Hessell A, Rakasz E, Tehrani D, Huber M, Weisgrau K, Landucci G, Forthal D, Koff W, Poignard P, Watkins D, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10, directed against the human immunodeficiency virus type 1 (HIV-1) gp41 membrane proximal external region (MPER), protect against SHIVBa-L mucosal challenge. J Virol 2010; 84: 1302-1113.
13. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157: 2168-2173.
14. Lambotte O, Ferrari G, Moog C, Yates NL, Liao H-X, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23: 897-906.
15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-2220.
16. Cummins LM, Weinhold KJ, Matthews TJ, Langlois AJ, Perno CF, Condie RM, Allain JP. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 1991; 77: 1111-1117.
17. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 1999; 73: 8966-8974.
18. Perfetto SP, Ambrozak D, Nguyen R, Chattopadhyay P, Roederer M. Quality assurance for polychromatic flow cytometry. Nat Protoc 2006; 1: 1522-1530.
19. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, Wieczorek L, Brown B, Polonis V, West JT, et al. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010; 408: 1-13.
20. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59: 284-291.
21. O'Doherty U, Swiggard WJ, Malim MH. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000; 74: 10074-10080.
22. Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, Ochsenbauer C, Edmonds TG, Kappes JC, Cunningham CK, et al. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 2010; 84: 4998-5006.
23. Liu L, Chahroudi A, Silvestri G, Wernett ME, Kaiser WJ, Safrit JT, Komoriya A, Altman JD, Packard BZ, Feinberg MB. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med 2002; 8: 185-189.
24. Packard BZ, Telford WG, Komoriya A, Henkart PA. Granzyme B activity in target cells detects attack by cytotoxic lymphocytes. J Immunol 2007; 179: 3812-3820.
25. Clopper C, Pearson ES. The use of confidence of fiducial limits illustrated in the case of bnomial. Biometrika 1934; 26: 404-413.
26. Chambers JM. Linear models. In: Chanders JM, Hastie TJ, editors. Statistical Models in S. New York: Chapman & Hall/CRC; 1992. pp 95-144.
27. Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepapeliere P, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25: 510-518.
28. Tyler DS, Stanley SD, Zolla-Pazner S, Gorny MK, Shadduck PP, Langlois AJ, Matthews TJ, Bolognesi DP, Palker TJ, Weinhold KJ. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 1990; 145: 3276-3282.
29. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I. The utility of ADCC responses in HIV infection. Curr HIV Res 2008; 6: 515-519.
30. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol 2009; 182: 1202-1210.
31. Liu Q, Sun Y, Rihn S, Nolting A, Tsoukas PN, Jost S, Cohen K, Walker B, Alter G. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009; 83: 8705-8712.
32. Broliden K, Von Gegerfelt A, Persson C, Horal P, Svennerholm B, Wahren B, Bjorling E, Vahlne A. Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity. AIDS Res Hum Retroviruses 1996; 12: 1699-1702.
33. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157: 2168-2173.
34. Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008; 82: 5450-5459.
35. Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Papathanasopoulos MA, Gray GE, Sherman GG, Coovadia AH, Kuhn L. Cutting edge: Unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1. J Immunol 2009; 182: 5914-5918.